Cell-free DNA from nail clippings as source of normal control for genomic studies in hematologic malignancies
Comprehensive genomic sequencing is becoming a critical component in the assessment of hematologic malignancies, with broad implications for patients’ management. In this context, unequivocally discriminating somatic from germline events is challenging but greatly facilitated by matched analysis of...
Saved in:
Published in | Haematologica (Roma) Vol. 109; no. 10; pp. 3269 - 3281 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Italy
Fondazione Ferrata Storti
01.10.2024
Ferrata Storti Foundation |
Subjects | |
Online Access | Get full text |
ISSN | 0390-6078 1592-8721 1592-8721 |
DOI | 10.3324/haematol.2024.285054 |
Cover
Abstract | Comprehensive genomic sequencing is becoming a critical component in the assessment of hematologic malignancies, with broad implications for patients’ management. In this context, unequivocally discriminating somatic from germline events is challenging but greatly facilitated by matched analysis of tumor:normal pairs of samples. In contrast to solid tumors, in hematologic malignancies conventional sources of normal control material (peripheral blood, buccal swabs, saliva) could be highly involved by the neoplastic process, rendering them unsuitable. In this work we describe our real-world experience using cell-free DNA (cfDNA) isolated from nail clippings as an alternate source of normal control material, through the dedicated review of 2,610 tumor:nail pairs comprehensively sequenced by MSK-IMPACT-heme. Overall, we found that nail cfDNA is a robust germline control for paired genomic studies. In a subset of patients, nail DNA may be contaminated by tumor DNA, reflecting unique attributes of the hematologic disease and transplant history. Contamination is generally low level, but significantly more common among patients with myeloid neoplasms (20.5%; 304/1,482) than among those with lymphoid diseases (5.4%; 61/1,128) and particularly enriched in myeloproliferative neoplasms with marked myelofibrosis. When identified in patients with lymphoid and plasma-cell neoplasms, mutations commonly reflected a myeloid profile and correlated with a concurrent/evolving clonal myeloid neoplasm. Donor DNA was identified in 22% (11/50) of nails collected after allogeneic stem-cell transplantation. In this cohort, an association with a recent history of graft-versus-host disease was identified. These findings should be considered as a potential limitation to the use of nails as a source of normal control DNA but could also provide important diagnostic information regarding the disease process. |
---|---|
AbstractList | Comprehensive genomic sequencing is becoming a critical component in the assessment of hematologic malignancies, with broad implications for patient management. In this context, unequivocally discriminating somatic from germline events is challenging but greatly facilitated by matched analysis of tumor:normal pairs. In contrast to solid tumors, conventional sources of normal control (peripheral blood, buccal swabs, saliva) could be highly involved by the neoplastic process, rendering them unsuitable. In this work we describe our real-world experience using cell free DNA (cfDNA) isolated from nail clippings as an alternate source of normal control, through the dedicated review of 2,610 tumor:nail pairs comprehensively sequenced by MSK-IMPACT-heme. Overall, we find nail cfDNA is a robust source of germline control for paired genomic studies. In a subset of patients, nail DNA may have tumor DNA contamination, reflecting unique attributes of the hematologic disease and transplant history. Contamination is generally low level, but significantly more common among patients with myeloid neoplasms (20.5%; 304/1482) compared to lymphoid diseases (5.4%; 61/1128) and particularly enriched in myeloproliferative neoplasms with marked myelofibrosis. When identified in patients with lymphoid and plasma-cell neoplasms, mutations commonly reflected a myeloid profile and correlated with a concurrent/evolving clonal myeloid neoplasm. For nails collected after allogeneic stem-cell transplantation, donor DNA was identified in 22% (11/50). In this cohort, an association with recent history of graft-vs-host disease was identified. These findings should be considered as a potential limitation for the use of nail as normal control but could also provide important diagnostic information regarding the disease process. Comprehensive genomic sequencing is becoming a critical component in the assessment of hematologic malignancies, with broad implications for patients’ management. In this context, unequivocally discriminating somatic from germline events is challenging but greatly facilitated by matched analysis of tumor:normal pairs of samples. In contrast to solid tumors, in hematologic malignancies conventional sources of normal control material (peripheral blood, buccal swabs, saliva) could be highly involved by the neoplastic process, rendering them unsuitable. In this work we describe our real-world experience using cell-free DNA (cfDNA) isolated from nail clippings as an alternate source of normal control material, through the dedicated review of 2,610 tumor:nail pairs comprehensively sequenced by MSK-IMPACT-heme. Overall, we found that nail cfDNA is a robust germline control for paired genomic studies. In a subset of patients, nail DNA may be contaminated by tumor DNA, reflecting unique attributes of the hematologic disease and transplant history. Contamination is generally low level, but significantly more common among patients with myeloid neoplasms (20.5%; 304/1,482) than among those with lymphoid diseases (5.4%; 61/1,128) and particularly enriched in myeloproliferative neoplasms with marked myelofibrosis. When identified in patients with lymphoid and plasma-cell neoplasms, mutations commonly reflected a myeloid profile and correlated with a concurrent/evolving clonal myeloid neoplasm. Donor DNA was identified in 22% (11/50) of nails collected after allogeneic stem-cell transplantation. In this cohort, an association with a recent history of graft-versus-host disease was identified. These findings should be considered as a potential limitation to the use of nails as a source of normal control DNA but could also provide important diagnostic information regarding the disease process. Comprehensive genomic sequencing is becoming a critical component in the assessment of hematologic malignancies, with broad implications for patients' management. In this context, unequivocally discriminating somatic from germline events is challenging but greatly facilitated by matched analysis of tumor:normal pairs of samples. In contrast to solid tumors, in hematologic malignancies conventional sources of normal control material (peripheral blood, buccal swabs, saliva) could be highly involved by the neoplastic process, rendering them unsuitable. In this work we describe our real-world experience using cell-free DNA (cfDNA) isolated from nail clippings as an alternate source of normal control material, through the dedicated review of 2,610 tumor:nail pairs comprehensively sequenced by MSK-IMPACT-heme. Overall, we found that nail cfDNA is a robust germline control for paired genomic studies. In a subset of patients, nail DNA may be contaminated by tumor DNA, reflecting unique attributes of the hematologic disease and transplant history. Contamination is generally low level, but significantly more common among patients with myeloid neoplasms (20.5%; 304/1,482) than among those with lymphoid diseases (5.4%; 61/1,128) and particularly enriched in myeloproliferative neoplasms with marked myelofibrosis. When identified in patients with lymphoid and plasma-cell neoplasms, mutations commonly reflected a myeloid profile and correlated with a concurrent/evolving clonal myeloid neoplasm. Donor DNA was identified in 22% (11/50) of nails collected after allogeneic stem-cell transplantation. In this cohort, an association with a recent history of graft-versus-host disease was identified. These findings should be considered as a potential limitation to the use of nails as a source of normal control DNA but could also provide important diagnostic information regarding the disease process.Comprehensive genomic sequencing is becoming a critical component in the assessment of hematologic malignancies, with broad implications for patients' management. In this context, unequivocally discriminating somatic from germline events is challenging but greatly facilitated by matched analysis of tumor:normal pairs of samples. In contrast to solid tumors, in hematologic malignancies conventional sources of normal control material (peripheral blood, buccal swabs, saliva) could be highly involved by the neoplastic process, rendering them unsuitable. In this work we describe our real-world experience using cell-free DNA (cfDNA) isolated from nail clippings as an alternate source of normal control material, through the dedicated review of 2,610 tumor:nail pairs comprehensively sequenced by MSK-IMPACT-heme. Overall, we found that nail cfDNA is a robust germline control for paired genomic studies. In a subset of patients, nail DNA may be contaminated by tumor DNA, reflecting unique attributes of the hematologic disease and transplant history. Contamination is generally low level, but significantly more common among patients with myeloid neoplasms (20.5%; 304/1,482) than among those with lymphoid diseases (5.4%; 61/1,128) and particularly enriched in myeloproliferative neoplasms with marked myelofibrosis. When identified in patients with lymphoid and plasma-cell neoplasms, mutations commonly reflected a myeloid profile and correlated with a concurrent/evolving clonal myeloid neoplasm. Donor DNA was identified in 22% (11/50) of nails collected after allogeneic stem-cell transplantation. In this cohort, an association with a recent history of graft-versus-host disease was identified. These findings should be considered as a potential limitation to the use of nails as a source of normal control DNA but could also provide important diagnostic information regarding the disease process. |
Author | Lachhander, Sean Rana, Satshil Wang, Wei Perales, Miguel-Angel Ponce, Doris Yun, Anita Arcila, Maria E. Durham, Benjamin Gedvilaite, Erika Krystel-Whittemore, Melissa Rema, Anoop Balakrishnan Ptashkin, Ryan N. Kumar, Jyoti Bowman, Anita S. Salles, Gilles Birsoy, Ozge Zehir, Ahmet Kiecka, Iwona Giralt, Sergio Lin, Yun-Te Mantha, Simon Roshal, Mikhail Vanderbilt, Chad Dogan, Ahmet Brannon, A. Rose Benayed, Ryma Ladanyi, Marc Markova, Alina Petrova-Drus, Kseniya Zhu, Menglei Xiao, Wenbin Benhamida, Jamal Jakubowski, Ann Nafa, Khedoudja Mandelker, Diana Casanova, Jacklyn Liu, Ying Mohanty, Abhinita S. Stein, Eytan M. Ewalt, Mark D. Rampal, Raajit Salazar, Paulo Haque, Mohammad S. Chaves, Nelio Yao, JinJuan Rijo, Ivelise Berger, Michael F. Horwitz, Steven |
AuthorAffiliation | 2 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA 1 Department of Pathology and Laboratory Medicine |
AuthorAffiliation_xml | – name: 2 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA – name: 1 Department of Pathology and Laboratory Medicine |
Author_xml | – sequence: 1 givenname: Melissa surname: Krystel-Whittemore fullname: Krystel-Whittemore, Melissa – sequence: 2 givenname: Kseniya surname: Petrova-Drus fullname: Petrova-Drus, Kseniya – sequence: 3 givenname: Ryan N. surname: Ptashkin fullname: Ptashkin, Ryan N. – sequence: 4 givenname: Mark D. surname: Ewalt fullname: Ewalt, Mark D. – sequence: 5 givenname: JinJuan surname: Yao fullname: Yao, JinJuan – sequence: 6 givenname: Ying surname: Liu fullname: Liu, Ying – sequence: 7 givenname: Menglei surname: Zhu fullname: Zhu, Menglei – sequence: 8 givenname: Jamal surname: Benhamida fullname: Benhamida, Jamal – sequence: 9 givenname: Benjamin surname: Durham fullname: Durham, Benjamin – sequence: 10 givenname: Jyoti surname: Kumar fullname: Kumar, Jyoti – sequence: 11 givenname: Khedoudja surname: Nafa fullname: Nafa, Khedoudja – sequence: 12 givenname: Iwona surname: Kiecka fullname: Kiecka, Iwona – sequence: 13 givenname: Anita S. surname: Bowman fullname: Bowman, Anita S. – sequence: 14 givenname: Erika surname: Gedvilaite fullname: Gedvilaite, Erika – sequence: 15 givenname: Jacklyn surname: Casanova fullname: Casanova, Jacklyn – sequence: 16 givenname: Yun-Te surname: Lin fullname: Lin, Yun-Te – sequence: 17 givenname: Abhinita S. surname: Mohanty fullname: Mohanty, Abhinita S. – sequence: 18 givenname: Satshil surname: Rana fullname: Rana, Satshil – sequence: 19 givenname: Anoop Balakrishnan surname: Rema fullname: Rema, Anoop Balakrishnan – sequence: 20 givenname: Ivelise surname: Rijo fullname: Rijo, Ivelise – sequence: 21 givenname: Nelio surname: Chaves fullname: Chaves, Nelio – sequence: 22 givenname: Paulo surname: Salazar fullname: Salazar, Paulo – sequence: 23 givenname: Anita surname: Yun fullname: Yun, Anita – sequence: 24 givenname: Sean surname: Lachhander fullname: Lachhander, Sean – sequence: 25 givenname: Wei surname: Wang fullname: Wang, Wei – sequence: 26 givenname: Mohammad S. surname: Haque fullname: Haque, Mohammad S. – sequence: 27 givenname: Wenbin surname: Xiao fullname: Xiao, Wenbin – sequence: 28 givenname: Mikhail surname: Roshal fullname: Roshal, Mikhail – sequence: 29 givenname: Sergio surname: Giralt fullname: Giralt, Sergio – sequence: 30 givenname: Gilles surname: Salles fullname: Salles, Gilles – sequence: 31 givenname: Raajit surname: Rampal fullname: Rampal, Raajit – sequence: 32 givenname: Eytan M. surname: Stein fullname: Stein, Eytan M. – sequence: 33 givenname: Miguel-Angel surname: Perales fullname: Perales, Miguel-Angel – sequence: 34 givenname: Steven surname: Horwitz fullname: Horwitz, Steven – sequence: 35 givenname: Ann surname: Jakubowski fullname: Jakubowski, Ann – sequence: 36 givenname: Doris surname: Ponce fullname: Ponce, Doris – sequence: 37 givenname: Alina surname: Markova fullname: Markova, Alina – sequence: 38 givenname: Ozge surname: Birsoy fullname: Birsoy, Ozge – sequence: 39 givenname: Diana surname: Mandelker fullname: Mandelker, Diana – sequence: 40 givenname: Simon surname: Mantha fullname: Mantha, Simon – sequence: 41 givenname: Ahmet surname: Dogan fullname: Dogan, Ahmet – sequence: 42 givenname: Ryma surname: Benayed fullname: Benayed, Ryma – sequence: 43 givenname: Marc surname: Ladanyi fullname: Ladanyi, Marc – sequence: 44 givenname: Michael F. surname: Berger fullname: Berger, Michael F. – sequence: 45 givenname: A. Rose surname: Brannon fullname: Brannon, A. Rose – sequence: 46 givenname: Ahmet surname: Zehir fullname: Zehir, Ahmet – sequence: 47 givenname: Chad surname: Vanderbilt fullname: Vanderbilt, Chad – sequence: 48 givenname: Maria E. surname: Arcila fullname: Arcila, Maria E. |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38450530$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kk1v1DAQhi1URLeFf4CQj1yyOP5IYi6oWihUquACZ8sZT7KuEnuxs5X493i7XUQ5cLGlmXee8XjeC3IWYkBCXtdsLQSX77YWZ7vEac0Zl2veKabkM7KqleZV1_L6jKyY0KxqWNudk4uc7xjjTOv2BTkXnSxywVZk3uA0VUNCpB-_XtEhxZkG6ycKk9_tfBgztZnmuE-ANA40xDTbko1hSXGiQ0x0xBBnDzQve-cxUx_o9vi0OJZwkfsx2AAl95I8H-yU8dXjfUl-XH_6vvlS3X77fLO5uq1Atmqpat60ylmAhkHvHJTJoEGwWAvWcKZcj07VCmorHBtcL6VudI89doqDc624JDdHrov2zuySn236ZaL15iEQ02hsWjxMaFQrGsGcaJ0GqbC3GrTVHSA25YSusD4cWbt9P6MDLJPb6Qn0aSb4rRnjvalrKYXQvBDePhJS_LnHvJjZZyj_bgPGfTZcS153nWhkkb75u9mfLqeFFcH7owBSzDnhYMAvdvGHfZS1mZqZgzvMyR3m4A5zdEcplv8Un_j_LfsNwrnD1A |
CitedBy_id | crossref_primary_10_3324_haematol_2024_285055 crossref_primary_10_3324_haematol_2024_285371 |
Cites_doi | 10.1373/clinchem.2008.108225 10.1158/1055-9965.EPI-14-0552 10.1385/SCR:1:1:037 10.1038/s41467-023-42585-9 10.1038/nbt.2696 10.1373/clinchem.2006.085043 10.1016/j.cell.2006.07.024 10.1016/j.jmoldx.2014.02.004 10.1111/j.1467-2494.2007.00372.x 10.1016/j.bbmt.2010.09.001 10.1038/nature730 10.1097/00007691-200108000-00004 10.4236/ojepi.2015.51006 10.1186/2041-2223-2-23 10.1093/nar/9.17.4267 10.1007/s11864-023-01089-w 10.1371/journal.pone.0235146 10.1093/nar/gkw520 10.1038/s41409-020-0938-x 10.1038/ncb1132 10.1158/2159-8290.CD-11-0184 10.1177/10760296221097969 10.1182/bloodadvances.2020001636 10.1016/j.ajhg.2020.01.008 10.1164/rccm.200301-145OC 10.1177/154405910608501215 10.1006/excr.2000.5027 10.3390/ijms21113900 10.1038/nm.4333 10.1016/j.vibspec.2018.09.004 10.1016/S0002-9440(10)63203-8 10.1016/j.aanat.2011.03.013 10.1007/s00292-023-01234-0 10.1016/j.jmoldx.2014.12.006 10.1182/blood-2007-02-071423 10.1097/PAS.0b013e3180335f65 10.1038/s41598-018-31503-5 10.1016/j.clindermatol.2013.06.006 10.1016/j.tcb.2022.12.001 10.1038/s41525-022-00285-1 10.1016/S0140-6736(03)12894-2 10.1371/journal.pone.0017581 10.1158/1078-0432.1119.11.3 10.1038/35018642 10.1016/j.bbamcr.2013.06.010 10.7554/eLife.66395 10.3961/jpmph.2012.45.4.235 10.1038/sj.leu.2403789 10.1016/j.yjmcc.2021.07.004 10.1038/nature00870 10.1007/s004290050237 10.1007/s12024-018-0057-9 |
ContentType | Journal Article |
Copyright | Copyright© 2024 Ferrata Storti Foundation |
Copyright_xml | – notice: Copyright© 2024 Ferrata Storti Foundation |
DBID | AAYXX CITATION NPM 7X8 5PM DOA |
DOI | 10.3324/haematol.2024.285054 |
DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
DatabaseTitleList | PubMed MEDLINE - Academic CrossRef |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Anatomy & Physiology |
EISSN | 1592-8721 |
EndPage | 3281 |
ExternalDocumentID | oai_doaj_org_article_573630d37d9c45eba9c9a98cee698cc8 PMC11443392 38450530 10_3324_haematol_2024_285054 |
Genre | Journal Article |
GrantInformation_xml | – fundername: NCI NIH HHS grantid: P30 CA008748 |
GroupedDBID | --- 29I 2WC 53G 5GY 5RE 5VS AAFWJ AAYXX ADBBV AENEX AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV BTFSW CITATION CS3 DIK E3Z EBS EJD F5P FRP GROUPED_DOAJ H13 HYE KQ8 OK1 OVT P2P RHI RNS RPM SJN TFS TR2 W8F WOQ WOW NPM 7X8 5PM |
ID | FETCH-LOGICAL-c475t-12675dacc60cbddc054c6ecae1306205dbed515c1a3d0fdb44969bebe852cdd73 |
IEDL.DBID | DOA |
ISSN | 0390-6078 1592-8721 |
IngestDate | Wed Aug 27 01:25:18 EDT 2025 Tue Sep 30 17:07:12 EDT 2025 Fri Sep 05 02:54:20 EDT 2025 Mon Jul 21 06:02:49 EDT 2025 Wed Oct 01 04:59:31 EDT 2025 Thu Apr 24 22:50:54 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 10 |
Language | English |
License | http://creativecommons.org/licenses/by-nc/4.0 This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c475t-12675dacc60cbddc054c6ecae1306205dbed515c1a3d0fdb44969bebe852cdd73 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 MK-W has been an advisory board member and speaker for AstraZeneca and has provided professional services for Foundation Medicine. KPD has received an honorarium (not related to this study) from Invivoscribe, Inc. RNP is an employee of C2i Genomics. RR has received consulting fees from Incyte Corporation, Celgene/BMS, Blueprint, AbbVie, CTI, Stemline, Galecto, Pharmaessentia, Constellation/Morphosys, Sierra Oncology/GSK, Cogent, Sumitomo Dainippon, Kartos, Servier, Zentalis, and Karyopharm and has received research funding from Constellation Pharmaceuticals, Ryvu, Zentalis, and Stemline Therapeutics. MAP reports honoraria from Adicet, Allogene, Allovir, Caribou Biosciences, Celgene, Bristol-Myers Squibb, Equilium, Exevir, ImmPACT Bio, Incyte, Karyopharm, Kite/Gilead, Merck, Miltenyi Biotec, MorphoSys, Nektar Therapeutics, Novartis, Omeros, OrcaBio, Sanofi, Syncopation, VectivBio AG, and Vor Biopharma; he serves on Data Safety Monitoring Boards for Cidara Therapeutics, Medigene, and Sellas Life Sciences, and on a scientific advisory board of NexImmune; he has ownership interests in NexImmune, Omeros, and OrcaBio; and has received institutional research support for clinical trials from Allogene, Incyte, Kite/Gilead, Miltenyi Biotec, Nektar Therapeutics, and Novartis. SH is a consultant for Affimed, Abcuro Inc, Corvus, Daiichi Sankyo, Kyowa Hakko Kirin, ONO Pharmaceuticals, SeaGen, SecuraBio, Takeda, and Yingli; and has received research support from ADC Therapeutics, Affimed, C4, Celgene, Crispr Therapeutics, Daiichi Sankyo, Dren Kyowa Hakko Kirin, Millennium/Takeda, Seattle Genetics, and SecuraBio. DP has received honoraria from Incyte and Sanofi; has served on advisory boards for Evive Biotechnology (Shanghai) Ltd (formerly Generon [Shanghai] Corporation Ltd), Kadmon-Sanofi Corporation, Ceramedix, and Incyte; and has received research funding from Incyte Corporation and Sanofi. AM has received research funding from AstraZeneca, Incyte Corporation, Kintara Therapeutics, and Amryt Pharma; has provided consultancy services for ADC Therapeutics, Alira Health, AstraZeneca, Protagonist Therapeutics, OnQuality, and Janssen; and has received royalties from UpToDate. SM is the principal owner of Daboia Consulting LLC. AD receives research support from Roche and Takeda. MFB has provided consultancy services for Eli Lilly, AstraZeneca, and Paige.AI; has received research support from Boundless Bio; and has intellectual property rights with SOPHiA Genetics. CV holds equity and intellectual property rights with, and provides professional services and activities for Paige.AI. MEA has acted as a speaker for Biocartis, Invivoscribe, Physician Educational Resources (PER), Peerview Institute for Medical Education, Clinical Care Options, and RMEI Medical Education; and has acted as a consultant for Janssen Global Services, Bristol-Myers Squibb, AstraZeneca, Roche, Biocartis, and Sanofi. Disclosures |
OpenAccessLink | https://doaj.org/article/573630d37d9c45eba9c9a98cee698cc8 |
PMID | 38450530 |
PQID | 2942188364 |
PQPubID | 23479 |
PageCount | 13 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_573630d37d9c45eba9c9a98cee698cc8 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11443392 proquest_miscellaneous_2942188364 pubmed_primary_38450530 crossref_citationtrail_10_3324_haematol_2024_285054 crossref_primary_10_3324_haematol_2024_285054 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2024-10-01 |
PublicationDateYYYYMMDD | 2024-10-01 |
PublicationDate_xml | – month: 10 year: 2024 text: 2024-10-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | Italy |
PublicationPlace_xml | – name: Italy |
PublicationTitle | Haematologica (Roma) |
PublicationTitleAlternate | Haematologica |
PublicationYear | 2024 |
Publisher | Fondazione Ferrata Storti Ferrata Storti Foundation |
Publisher_xml | – name: Fondazione Ferrata Storti – name: Ferrata Storti Foundation |
References | 67188 67221 67189 67222 67182 67183 67180 67181 67186 67187 67220 67184 67185 67199 67190 67193 67194 67191 67192 67197 67198 67195 67196 67201 67169 67202 67200 67205 67206 67203 67204 67209 67207 67208 67179 67212 67213 67177 67210 67178 67211 67216 67217 67214 67215 67218 67219 67171 67172 67170 67175 67176 67173 67174 |
References_xml | – ident: 67181 doi: 10.1373/clinchem.2008.108225 – ident: 67185 doi: 10.1158/1055-9965.EPI-14-0552 – ident: 67219 doi: 10.1385/SCR:1:1:037 – ident: 67169 doi: 10.1038/s41467-023-42585-9 – ident: 67176 doi: 10.1038/nbt.2696 – ident: 67184 doi: 10.1373/clinchem.2006.085043 – ident: 67221 doi: 10.1016/j.cell.2006.07.024 – ident: 67187 doi: 10.1016/j.jmoldx.2014.02.004 – ident: 67193 doi: 10.1111/j.1467-2494.2007.00372.x – ident: 67213 doi: 10.1016/j.bbmt.2010.09.001 – ident: 67215 doi: 10.1038/nature730 – ident: 67183 doi: 10.1097/00007691-200108000-00004 – ident: 67186 doi: 10.4236/ojepi.2015.51006 – ident: 67178 doi: 10.1186/2041-2223-2-23 – ident: 67197 doi: 10.1093/nar/9.17.4267 – ident: 67202 doi: 10.1007/s11864-023-01089-w – ident: 67170 doi: 10.1371/journal.pone.0235146 – ident: 67174 doi: 10.1093/nar/gkw520 – ident: 67209 doi: 10.1038/s41409-020-0938-x – ident: 67214 doi: 10.1038/ncb1132 – ident: 67177 doi: 10.1158/2159-8290.CD-11-0184 – ident: 67203 doi: 10.1177/10760296221097969 – ident: 67204 doi: 10.1182/bloodadvances.2020001636 – ident: 67196 doi: 10.1016/j.ajhg.2020.01.008 – ident: 67210 doi: 10.1164/rccm.200301-145OC – ident: 67180 doi: 10.1177/154405910608501215 – ident: 67175 – ident: 67222 doi: 10.1006/excr.2000.5027 – ident: 67189 doi: 10.3390/ijms21113900 – ident: 67172 doi: 10.1038/nm.4333 – ident: 67171 doi: 10.1016/j.vibspec.2018.09.004 – ident: 67179 – ident: 67217 doi: 10.1016/S0002-9440(10)63203-8 – ident: 67194 doi: 10.1016/j.aanat.2011.03.013 – ident: 67205 doi: 10.1007/s00292-023-01234-0 – ident: 67173 doi: 10.1016/j.jmoldx.2014.12.006 – ident: 67207 doi: 10.1182/blood-2007-02-071423 – ident: 67191 doi: 10.1097/PAS.0b013e3180335f65 – ident: 67188 doi: 10.1038/s41598-018-31503-5 – ident: 67195 doi: 10.1016/j.clindermatol.2013.06.006 – ident: 67200 doi: 10.1016/j.tcb.2022.12.001 – ident: 67198 doi: 10.1038/s41525-022-00285-1 – ident: 67218 doi: 10.1016/S0140-6736(03)12894-2 – ident: 67199 doi: 10.1371/journal.pone.0017581 – ident: 67190 doi: 10.1158/1078-0432.1119.11.3 – ident: 67211 doi: 10.1038/35018642 – ident: 67192 doi: 10.1016/j.bbamcr.2013.06.010 – ident: 67206 doi: 10.7554/eLife.66395 – ident: 67182 doi: 10.3961/jpmph.2012.45.4.235 – ident: 67216 doi: 10.1038/sj.leu.2403789 – ident: 67201 doi: 10.1016/j.yjmcc.2021.07.004 – ident: 67220 doi: 10.1038/nature00870 – ident: 67212 doi: 10.1007/s004290050237 – ident: 67208 doi: 10.1007/s12024-018-0057-9 |
SSID | ssj0020997 |
Score | 2.4618137 |
Snippet | Comprehensive genomic sequencing is becoming a critical component in the assessment of hematologic malignancies, with broad implications for patients’... Comprehensive genomic sequencing is becoming a critical component in the assessment of hematologic malignancies, with broad implications for patient... Comprehensive genomic sequencing is becoming a critical component in the assessment of hematologic malignancies, with broad implications for patients'... |
SourceID | doaj pubmedcentral proquest pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 3269 |
SubjectTerms | Hematologic Malignancy |
Title | Cell-free DNA from nail clippings as source of normal control for genomic studies in hematologic malignancies |
URI | https://www.ncbi.nlm.nih.gov/pubmed/38450530 https://www.proquest.com/docview/2942188364 https://pubmed.ncbi.nlm.nih.gov/PMC11443392 https://doaj.org/article/573630d37d9c45eba9c9a98cee698cc8 |
Volume | 109 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
journalDatabaseRights | – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1592-8721 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0020997 issn: 0390-6078 databaseCode: KQ8 dateStart: 19940101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1592-8721 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0020997 issn: 0390-6078 databaseCode: DOA dateStart: 19940101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1592-8721 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0020997 issn: 0390-6078 databaseCode: DIK dateStart: 19940101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 1592-8721 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0020997 issn: 0390-6078 databaseCode: RPM dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlh9JLaZI-tmnDBEJvar16rXXcpgkhkJwayM3IemQNXm2JN4f--44k75IthVx68cGSkawZab6RZj4RcsoSQ4tkkgoEG1QYWVEtraRGBitYUD6wlJx8faMub8XVnbx7ctVXigkr9MBl4NBh54pXjs-ctkL61mirja5xbVf4tDnNF83YxpkaXa2UD5rPDzQ6R2gFS9IcR_TwbWESGeoqHTsw8ZXVCAHEjlHK3P3_Apx_x00-MUQXb8jrEUHCvPR8n7zw8YAcziO2tvwNXyDHdObN8gPy8no8Oj8kyzPf9zQ8eA8_buaQ0kogmq4H22eOhvsBzABlLx9WAWICs1haQtkBsS0kPtdlZ2EosYfQRViUv0zrJ2D17r7c9ju8JbcX5z_PLul41wK1YibXdMrQc3DGWlXZ1jmLg2KVt8ajjVOskq71DqGPnRruquBaIbTSLWpALZl1bsbfkb24iv4DgdBq00qHrq9I3PQzI23wXDrFzDSg1CaEbwa7sSMReboPo2_QIUkiajYiapKImiKiCaHbr34VIo5n6n9PctzWTTTa-QUqVzMqV_Occk3IyUYLGpx26SzFRL96HBqmBYKjmits6H3Rim1TvEbFl7yakHpHX3b6slsSu0Wm9kbvVHCErB__R--PyKs0ICX08BPZWz88-s8IodbtcZ4tx3lv6w_PWRzJ |
linkProvider | Directory of Open Access Journals |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cell-free+DNA+from+nail+clippings+as+source+of+normal+control+for+genomic+studies+in+hematologic+malignancies&rft.jtitle=Haematologica+%28Roma%29&rft.au=Krystel-Whittemore%2C+Melissa&rft.au=Petrova-Drus%2C+Kseniya&rft.au=Ptashkin%2C+Ryan+N&rft.au=Ewalt%2C+Mark+D&rft.date=2024-10-01&rft.eissn=1592-8721&rft_id=info:doi/10.3324%2Fhaematol.2024.285054&rft_id=info%3Apmid%2F38450530&rft.externalDocID=38450530 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0390-6078&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0390-6078&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0390-6078&client=summon |